Search

Your search keyword '"Celli, Bartolome R."' showing total 384 results
Start Over Author "Celli, Bartolome R." Search Limiters Academic (Peer-Reviewed) Journals
384 results on '"Celli, Bartolome R."'

1. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

Author

Agusti, Alvar, Lopez-Campos, José Luis, Miravitlles, Marc, Soler-Cataluña, Juan Jose, Marin, Jose Maria, Cosio, Borja G., Alcázar-Navarrete, Bernardino, Echave-Sustaeta, Jose Maria, Casanova, Ciro, Peces-Barba, German, de-Torres, Juan Pablo, Fernandez-Villar, Alberto, Ancochea, Julio, Villar-Alvarez, Felipe, Roman-Rodriguez, Miguel, Molina, Jesus, Garcia-Rivero, Juan Luis, Gonzalez, Cruz, Sobradillo, Patricia, Faner, Rosa, Peña, Carolina, Sharma, Raj, Izquierdo, José Luis, and Celli, Bartolome R.

Published
2024
Full Text
View/download PDF

3. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

Author

de-Torres, Juan P., Casanova, Ciro, Marín, José M., Cabrera, Carlos, Marín, Marta, Ezponda, Ana, Cosio, Borja G., Martínez, Cristina, Solanes, Ingrid, Fuster, Antonia, Calle, Myriam, Peces-Barba, Germán, Gotera, Carolina, Feu-Collado, Nuria, Marin, Alicia, Alcaide, Ana Belén, Sangro, Matilde, Bastarrika, Gorka, and Celli, Bartolome R.

Published
2024
Full Text
View/download PDF

5. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Author

Agustí, Alvar, Celli, Bartolome R., Criner, Gerard J., Halpin, David, Anzueto, Antonio, Barnes, Peter, Bourbeau, Jean, Han, MeiLan K., Martinez, Fernando J., Montes de Oca, Maria, Mortimer, Kevin, Papi, Alberto, Pavord, Ian, Roche, Nicolas, Salvi, Sundeep, Sin, Don D., Singh, Dave, Stockley, Robert, López Varela, M. Victorina, Wedzicha, Jadwiga A., and Vogelmeier, Claus F.

Published
2023
Full Text
View/download PDF

7. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

Author

Rabe, Klaus F, Celli, Bartolome R, Wechsler, Michael E, Abdulai, Raolat M, Luo, Xiaodong, Boomsma, Maarten M, Staudinger, Heribert, Horowitz, Julie E, Baras, Aris, Ferreira, Manuel A, Ruddy, Marcella K, Nivens, Michael C, Amin, Nikhil, Weinreich, David M, Yancopoulos, George D, and Goulaouic, Helene

Published
2021
Full Text
View/download PDF

11. Sex differences between women and men with COPD: A new analysis of the 3CIA study

Author

Perez, Tamara Alonso, Castillo, Elena García, Ancochea, Julio, Pastor Sanz, María Teresa, Almagro, Pere, Martínez-Camblor, Pablo, Miravitlles, Marc, Rodríguez-Carballeira, Mónica, Navarro, Annie, Lamprecht, Bernd, Ramírez-García Luna, Ana S., Kaiser, Bernhard, Alfageme, Inmaculada, Casanova, Ciro, Esteban, Cristóbal, Soler-Cataluña, Juan J., De-Torres, Juan P., Celli, Bartolomé R., Marin, Jose M., Lopez-Campos, Jose L., Riet, Gerben Ter, Sobradillo, Patricia, Lange, Peter, Garcia-Aymerich, Judith, Anto, Josep M., Turner, Alice M., Han, MeiLan K., Langhammer, Arnulf, Sternberg, Alice, Leivseth, Linda, Bakke, Per, Johannessen, Ane, Oga, Toru, Cosío, Borja, Echazarreta, Andres, Roche, Nicolas, Burgel, Pierre-Régis, Sin, Don D., Puhan, Milo A., and Soriano, Joan B.

Published
2020
Full Text
View/download PDF

17. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

Author

Vogelmeier, Claus F., Criner, Gerard J., Martinez, Fernando J., Anzueto, Antonio, Barnes, Peter J., Bourbeau, Jean, Celli, Bartolome R., Chen, Rongchang, Decramer, Marc, Fabbri, Leonardo M., Frith, Peter, Halpin, David M.G., Varela, M. Victorina López, Nishimura, Masaharu, Roche, Nicolas, Rodriguez-Roisin, Roberto, Sin, Don D., Singh, Dave, Stockley, Robert, Vestbo, Jørgen, Wedzicha, Jadwiga A., and Agusti, Alvar

Published
2017
Full Text
View/download PDF

18. Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD

Author

Vogelmeier, Claus F., Criner, Gerard J., Martínez, Fernando J., Anzueto, Antonio, Barnes, Peter J., Bourbeau, Jean, Celli, Bartolome R., Chen, Rongchang, Decramer, Marc, Fabbri, Leonardo M., Frith, Peter, Halpin, David M.G., López Varela, M. Victorina, Nishimura, Masaharu, Roche, Nicolás, Rodríguez-Roisin, Roberto, Sin, Don D., Singh, Dave, Stockley, Robert, Vestbo, Jørgen, Wedzicha, Jadwiga A., and Agustí, Alvar

Published
2017
Full Text
View/download PDF

20. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study

Author

Andrianopoulos, Vasileios, Celli, Bartolome R., Franssen, Frits M.E., Pinto-Plata, Victor M., Calverley, Peter M.A., Vanfleteren, Lowie E.G.W., Vogiatzis, Ioannis, Vestbo, Jørgen, Agusti, Alvar, Bakke, Per S., Rennard, Stephen I., MacNee, William, Tal-Singer, Ruth, Yates, Julie C., Wouters, Emiel F.M., and Spruit, Martijn A.

Published
2016
Full Text
View/download PDF

23. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook.

Author

Rabe, Klaus F., Rennard, Stephen, Martinez, Fernando J., Celli, Bartolome R., Singh, Dave, Papi, Alberto, Bafadhel, Mona, Heble, Jigna, Radwan, Amr, Soler, Xavier, Nara, Juby A. Jacob, Deniz, Yamo, and Rowe, Paul J.

Subjects
CHRONIC obstructive pulmonary disease, INNATE lymphoid cells, PHOSPHODIESTERASE inhibitors, DISEASE exacerbation, INFLAMMATION
Abstract

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with a significant impact on patients' lives, including morbidity and mortality, and significant healthcare costs. Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD. However, many patients remain symptomatic, with persistent symptoms and/or acute exacerbations and progressive lung function loss. Although neutrophilic inflammation is the most common type of inflammation in COPD, 20-40% of patients with COPD exhibit type 2 inflammation, with roles for CD4+ (cluster of differentiation 4) T-helper cell type 1 cells, type 2 innate lymphoid cells, eosinophils, and alternatively activated macrophages. On the basis of the current limitations of available therapies, a significant unmet need exists in COPD management, including the need for targeted therapies to address the underlying pathophysiology leading to disease progression, such as type 2 inflammation, as well as biomarkers to help select the patients who would most benefit from the new therapies. Significant progress is being made, with evolving understanding of the pathobiology of COPD leading to novel therapeutic targets including epithelial alarmins. In this review, we describe the current therapeutic landscape in COPD, discuss unmet treatment needs, review the current knowledge of type 2 inflammation and epithelial alarmins in COPD, explore potential biomarkers of type 2 inflammation in COPD, and finally provide a rationale for incorporating therapies targeting type 2 inflammation and epithelial alarmins in COPD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Gold 2023: Highlights for primary care.

Author

Agustí, Alvar, Sisó-Almirall, Antoni, Roman, Miguel, Vogelmeier, Claus F., On behalf of the members of the Scientific Committee of GOLD (Appendix), Anzueto, Antonio, Barnes, Peter, Bourbeau, Jean, Celli, Bartolome R., Criner, Gerard J., Halpin, David, Han, MeiLan K., Martinez, Fernando J., de Oca, Maria Montes, Mortimer, Kevin, Papi, Alberto, Pavord, Ian, Roche, Nicolas, Salvi, Sundeep, and Sin, Don D.

Published
2023
Full Text
View/download PDF

25. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.

Author

Cazzola, Mario, Page, Clive P., Wedzicha, Jadwiga A., Celli, Bartolome R., Anzueto, Antonio, and Matera, Maria Gabriella

Subjects
OXIDATIVE stress, OBSTRUCTIVE lung diseases, CHRONIC obstructive pulmonary disease
Abstract

Background: Oxidative stress and persistent airway inflammation are thought to be important contributors to the development of chronic obstructive pulmonary disease (COPD). This review summarizes the evidence for targeting oxidative stress and inflammation in patients with COPD with mucolytic/antioxidant thiols and inhaled corticosteroids (ICS), either alone or in combination. Main body: Oxidative stress is increased in COPD, particularly during acute exacerbations. It can be triggered by oxidant air pollutants and cigarette smoke and/or by endogenous reactive oxygen species (ROS) released from mitochondria and activated inflammatory, immune and epithelial cells in the airways, together with a reduction in endogenous antioxidants such as glutathione (GSH). Oxidative stress also drives chronic inflammation and disease progression in the airways by activating intracellular signalling pathways and the release of further inflammatory mediators. ICS are anti-inflammatory agents currently recommended for use with long-acting bronchodilators to prevent exacerbations in patients with moderate-to-severe COPD, especially those with eosinophilic airway inflammation. However, corticosteroids can also increase oxidative stress, which may in turn reduce corticosteroid sensitivity in patients by several mechanisms. Thiol-based agents such as erdosteine, N-acetyl L-cysteine (NAC) and S-carboxymethylcysteine (S-CMC) are mucolytic agents that also act as antioxidants. These agents may reduce oxidative stress directly through the free sulfhydryl groups, serving as a source of reducing equivalents and indirectly though intracellular GSH replenishment. Few studies have compared the effects of corticosteroids and thiol agents on oxidative stress, but there is some evidence for greater antioxidant effects when they are administered together. The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) report supports treatment with antioxidants (erdosteine, NAC, S-CMC) in addition to standard-of-care therapy as they have been demonstrated to reduce COPD exacerbations. However, such studies have demonstrated that NAC and S-CMC reduced the exacerbation risk only in patients not treated with ICS, whereas erdosteine reduced COPD exacerbations irrespective of concomitant ICS use suggesting that erdosteine has additional pharmacological actions to ICS. Conclusions: Further clinical trials of antioxidant agents with and without ICS are needed to better understand the place of thiol-based drugs in the treatment of patients with COPD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

Author

Criner, Gerard J., Bourbeau, Jean, Diekemper, Rebecca L., Ouellette, Daniel R., Goodridge, Donna, Hernandez, Paul, Curren, Kristen, Balter, Meyer S., Bhutani, Mohit, Camp, Pat G., Celli, Bartolome R., Dechman, Gail, Dransfield, Mark T., Fiel, Stanley B., Foreman, Marilyn G., Hanania, Nicola A., Ireland, Belinda K., Marchetti, Nathaniel, Marciniuk, Darcy D., Mularski, Richard A., Ornelas, Joseph, Road, Jeremy D., and Stickland, Michael K.

Published
2015
Full Text
View/download PDF

28. Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

Author

Criner, Gerard J., Bourbeau, Jean, Diekemper, Rebecca L., Ouellette, Daniel R., Goodridge, Donna, Hernandez, Paul, Curren, Kristen, Balter, Meyer S., Bhutani, Mohit, Camp, Pat G., Celli, Bartolome R., Dechman, Gail, Dransfield, Mark T., Fiel, Stanley B., Foreman, Marilyn G., Hanania, Nicola A., Ireland, Belinda K., Marchetti, Nathaniel, Marciniuk, Darcy D., Mularski, Richard A., Ornelas, Joseph, Road, Jeremy D., and Stickland, Michael K.

Published
2015
Full Text
View/download PDF

33. Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice.

Author

Celli, Bartolome R., Fabbri, Leonardo M., Aaron, Shawn D., Agusti, Alvar, Brook, Robert D., Criner, Gerard J., Franssen, Frits M. E., Humbert, Marc, Hurst, John R., de Oca, Maria Montes, Pantoni, Leonardo, Papi, Alberto, Rodriguez-Roisin, Roberto, Sethi, Sanjay, Stolz, Daiana, Torres, Antoni, Vogelmeier, Claus F., and Wedzicha, Jadwiga A.

Abstract

Patients with chronic obstructive pulmonary disease (COPD) may suffer from acute episodes of worsening dyspnea, often associated with increased cough, sputum, and/or sputum purulence. These exacerbations of COPD (ECOPDs) impact health status, accelerate lung function decline, and increase the risk of hospitalization. Importantly, close to 20% of patients are readmitted within 30 days after hospital discharge, with great cost to the person and society. Approximately 25% and 65% of patients hospitalized for an ECOPD die within 1 and 5 years, respectively. Patients with COPD are usually older and frequently have concomitant chronic diseases, including heart failure, coronary artery disease, arrhythmias, interstitial lung diseases, bronchiectasis, asthma, anxiety, and depression, and are also at increased risk of developing pneumonia, pulmonary embolism, and pneumothorax. All of these morbidities not only increase the risk of subsequent ECOPDs but can also mimic or aggravate them. Importantly, close to 70% of readmissions after an ECOPD hospitalization result from decompensation of other morbidities. These observations suggest that in patients with COPD with worsening dyspnea but without the other classic characteristics of ECOPD, a careful search for these morbidities can help detect them and allow appropriate treatment. For most morbidities, a thorough clinical evaluation supplemented by appropriate clinical investigations can guide the healthcare provider to make a precise diagnosis. This perspective integrates the currently dispersed information available and provides a practical approach to patients with COPD complaining of worsening respiratory symptoms, particularly dyspnea. A systematic approach should help improve outcomes and the personal and societal cost of ECOPDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease

Author

Guerra, Beniamino, Haile, Sarah R., Lamprecht, Bernd, Ramírez, Ana S., Martinez-Camblor, Pablo, Kaiser, Bernhard, Alfageme, Inmaculada, Almagro, Pere, Casanova, Ciro, Esteban-González, Cristóbal, Soler-Cataluña, Juan J., de-Torres, Juan P., Miravitlles, Marc, Celli, Bartolome R., Marin, Jose M., ter Riet, Gerben, Sobradillo, Patricia, Lange, Peter, Garcia-Aymerich, Judith, Antó, Josep M., Turner, Alice M., Han, Meilan K., Langhammer, Arnulf, Leivseth, Linda, Bakke, Per, Johannessen, Ane, Oga, Toru, Cosio, Borja, Ancochea-Bermúdez, Julio, Echazarreta, Andres, Roche, Nicolas, Burgel, Pierre-Régis, Sin, Don D., Soriano, Joan B., Puhan, Milo A., and for the 3CIA collaboration

Published
2018
Full Text
View/download PDF

41. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease

Author

Celli, Bartolome R., Decramer, Marc, Wedzicha, Jadwiga A., Wilson, Kevin C., Agustí, Alvar, Criner, Gerard J., MacNee, William, Make, Barry J., Rennard, Stephen I., Stockley, Robert A., Vogelmeier, Claus, Anzueto, Antonio, Au, David H., Barnes, Peter J., Burgel, Pierre-Regis, Calverley, Peter M., Casanova, Ciro, Clini, Enrico M., Cooper, Christopher B., Coxson, Harvey O., Dusser, Daniel J., Fabbri, Leonardo M., Fahy, Bonnie, Ferguson, Gary T., Fisher, Andrew, Fletcher, Monica J., Hayot, Maurice, Hurst, John R., Jones, Paul W., Mahler, Donald A., Maltais, François, Mannino, David M., Martinez, Fernando J., Miravitlles, Marc, Meek, Paula M., Papi, Alberto, Rabe, Klaus F., Roche, Nicolas, Sciurba, Frank C., Sethi, Sanjay, Siafakas, Nikos, Sin, Don D., Soriano, Joan B., Stoller, James K., Tashkin, Donald P., Troosters, Thierry, Verleden, Geert M., Verschakelen, Johny, Vestbo, Jorgen, Walsh, John W., Washko, George R., Wise, Robert A., Wouters, Emiel F. M., and ZuWallack, Richard L.

Published
2015
Full Text
View/download PDF

44. International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials.

Author

Calverley, Peter M. A., Martinez, Fernando J., Vestbo, Jørgen, Jenkins, Christine R., Wise, Robert, Lipson, David A., Cowans, Nicholas J., Yates, Julie, Crim, Courtney, and Celli, Bartolome R.

Subjects
DISEASE progression, RESEARCH, ADRENOCORTICAL hormones, BRONCHODILATOR agents, OBSTRUCTIVE lung diseases, HOSPITAL care, RESEARCH funding
Abstract

Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) are an important endpoint in multinational clinical treatment trials, but the observed event rate is often lower than anticipated and appears to vary between countries. Objectives: We investigated whether systematic differences in national exacerbation rates might explain this observed variation. Methods: We reviewed data from three large multicenter international randomized trials conducted over an 18-year period with different designs and clinical severities of COPD, comparing bronchodilator and/or inhaled corticosteroids with bronchodilators alone and/or placebo. Exacerbations were defined by antibiotic and/or oral corticosteroid use (moderate) or need for hospitalization (severe). We calculated crude exacerbation rates in the 30 countries contributing 30 or more patients to at least two trials. We grouped data by exacerbation rate based on their first study contribution. Measurements and Main Results: For the 29,756 patients in 41 countries analyzed, the mean exacerbation rate was two- to threefold different between the highest and lowest tertiles of the recruiting nations. These differences were not explained by demographic features, study protocol, or reported exacerbation history at enrollment. Of the 18 countries contributing to all trials, half of those in the highest and half in the lowest tertiles of exacerbation history remained in these groups across trials. Severe exacerbations showed a different rank order internationally. Conclusions: Countries contributing to COPD trials differ consistently in their reporting of healthcare-defined exacerbations. These differences help explain why large studies have been needed to show differences between treatments that decrease exacerbation risk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Quantitative Computed Tomography Measures of Pectoralis Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study

Author

McDonald, Merry-Lynn N., Diaz, Alejandro A., Ross, James C., San Jose Estepar, Raul, Zhou, Linfu, Regan, Elizabeth A., Eckbo, Eric, Muralidhar, Nina, Come, Carolyn E., Cho, Michael H., Hersh, Craig P., Lange, Christoph, Wouters, Emiel, Casaburi, Richard H., Coxson, Harvey O., MacNee, William, Rennard, Stephen I., Lomas, David A., Agusti, Alvar, Celli, Bartolome R., Black-Shinn, Jennifer L., Kinney, Greg L., Lutz, Sharon M., Hokanson, John E., Silverman, Edwin K., and Washko, George R.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results